U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health,...
ChromaDex to Join Russell 2000® Index
ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen® supplement, backed by strong financial performance and a robust intellectual property portfolio LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide...
Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
NR improved the six-minute walking distance and treadmill walking time for those with PAD LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research, shares results from a milestone phase II clinical study...
Aquafil – Helping Define the Circular Business Model of the Future
Believes now is the time to move from a linear to a circular economic modelARCO, Italy, June 20, 2024 -- Aquafil SpA (ECNLF:OTCQX - ECNL:IM), based in Arco (TN) Italy and a pioneer of the circular economy, believes now is the time for business leaders to make a...
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
Clinical study results demonstrated that Niagen IV had no adverse side effects, provided superior tolerability, and a 75% shorter infusion time, with blood NAD+ levels peaking sooner and higher three hours post-infusion as compared to NAD+ IV. The U.S. FDA authorized...
ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
ChromaDex plans to conduct additional studies on NRC in anticipation of filing for an Investigational New Drug Application (IND) for the treatment of AT LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and...
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
LOS ANGELES - ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to...
Flow Beverage Corp. (FLOW) Company Webcast
I would like to welcome Flow Beverage Corp., a premium and sustainable water company. The ticker symbols are FLOW on the Toronto and FLWBF on the OTCQX. Presenting from the company today is Trent MacDonald, Chief Financial Officer. Flow is one of the fastest-growing...
Lincoln Educational Services (LINC) Company Webcast
For this presentation, we welcome Lincoln Educational Services Corporation, which trades on the NASDAQ under the ticker LINC. Joining us from the company is Scott Shaw, President and Chief Executive Officer, to give us an overview of the company. Lincoln Tech is a...
ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
LOS ANGELES - ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy-aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating...